title: Effects of route of administration and feeding schedule on pharmacokinetics of robenacoxib in cats.
abstract: OBJECTIVE
  To establish pharmacokinetics of robenacoxib after administration to cats via the IV, SC, and oral routes.
  
  
  METHODS
  24 cats.
  
  
  METHODS
  In a crossover design, robenacoxib was administered IV, SC, and orally (experiment 1) and orally (experiment 2) to cats with different feeding regimens. Blood robenacoxib concentrations were assayed, with a lower limit of quantification of 3 ng/mL.
  
  
  RESULTS
  In experiment 1, geometric mean pharmacokinetic values after IV administration of robenacoxib were as follows: blood clearance, 0.44 L/kg/h; plasma clearance, 0.29 L/kg/h; elimination half-life, 1.49 hours; and volume of distribution at steady state (determined from estimated plasma concentrations), 0.13 L/kg. Mean bioavailability was 69% and median time to maximum concentration (Cmax) was 1 hour for cats after SC administration of robenacoxib, whereas mean bioavailability was 49% and 10% and median time to Cmax was 1 hour and 30 minutes after oral administration to cats after food withholding and after cats were fed their entire ration, respectively. In experiment 2, geometric mean Cmax was 1,159, 1,201, and 692 ng/mL and area under the curve from 0 to infinity was 1,337, 1,383, and 1,069 ng × h/mL following oral administration to cats after food withholding, cats fed one-third of the daily ration, and cats fed the entire daily ration, respectively.
  
  
  CONCLUSIONS
  For treatment of acute conditions in cats, it is recommended to administer robenacoxib by IV or SC injection, orally after food withholding, or orally with a small amount of food to obtain optimal bioavailability and Cmax.
authors: Clinical Development, Novartis Animal Health Inc, Schwarzwaldallee 215, CH-4058, Basel, Switzerland. jonathan.king@novartis.com
authors: Jonathan N
authors: JN
authors: King
authors: Martin
authors: M
authors: Jung
authors: Max P
authors: MP
authors: Maurer
authors: Vincent B
authors: VB
authors: Schmid
authors: Wolfgang
authors: W
authors: Seewald
authors: Peter
authors: P
authors: Lees
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001682:Biological Availability; D002415:Cats / Q000097:blood / Q000378:metabolism*; D018592:Cross-Over Studies; D004159:Diphenylamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D005260:Female; D006207:Half-Life; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D010648:Phenylacetates / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D011897:Random Allocation
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010648:Phenylacetates; D004159:Diphenylamine; C551524:robenacoxib